Initiated Buy X

RGEN Repligen

TD Cowen

$200

Initiated Hold X

RGEN Repligen

Canaccord Genuity

$165

Initiated Peer Perform X

RGEN Repligen

Wolfe Research

Initiated Overweight X

RGEN Repligen

Wells Fargo

$180

Upgrades Hold Buy X

RGEN Repligen

Deutsche Bank

$180 $155

Initiated Neutral X

RGEN Repligen

Guggenheim

Downgrades Buy Hold X

RGEN Repligen

The Benchmark Company

Initiated Overweight X

RGEN Repligen

Wells Fargo

$185

Resumed Overweight X

RGEN Repligen

JP Morgan

$220

Initiated Buy X

RGEN Repligen

The Benchmark Company

$230

Initiated Hold X

RGEN Repligen

Deutsche Bank

$180

Initiated Sector Perform X

RGEN Repligen

RBC Capital Mkts

$190

Initiated Buy X

RGEN Repligen

UBS

$213

Initiated Outperform X

RGEN Repligen

Exane BNP Paribas

$330

Upgrades Neutral Buy X

RGEN Repligen

H.C. Wainwright

$110

Downgrades Buy Neutral X

RGEN Repligen

CL King

Initiated Neutral X

RGEN Repligen

H.C. Wainwright

$49

RGEN  Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.